Comparative Pharmacology
Head-to-head clinical analysis: ADPHEN versus SANOREX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADPHEN versus SANOREX.
ADPHEN vs SANOREX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Adphen is a combination of phentermine hydrochloride and diethylpropion hydrochloride. Phentermine is a sympathomimetic amine that acts as an appetite suppressant by stimulating the hypothalamus to release norepinephrine, thereby reducing food intake. Diethylpropion also has sympathomimetic activity, though its exact mechanism is not fully understood.
Serotonin 5-HT2C receptor agonist; stimulates pro-opiomelanocortin (POMC) neurons, leading to release of α-melanocyte-stimulating hormone (α-MSH) and activation of melanocortin-4 receptors in the hypothalamus, reducing appetite.
5 mg orally once daily, titrated to a maximum of 10 mg once daily as tolerated.
Oral: 1 mg twice daily for 12 weeks; maximum dose: 2 mg/day.
None Documented
None Documented
Terminal elimination half-life is 10-15 hours in adults with normal renal function; prolonged to 20-30 hours in severe renal impairment (CrCl <30 mL/min).
Terminal elimination half-life: 2-4 hours; context: requires multiple daily dosing to maintain therapeutic effect.
Primarily renal (70-90% as unchanged drug) with minor biliary (10-15% as metabolites). Fecal elimination is negligible (<5%).
Renal: 90% unchanged; biliary/fecal: 10%
Category C
Category C
Anorexiant
Anorexiant